R1 Therapeutics Expands Series A to $80.5M

R1 Therapeutics expanded its Series A financing to $80.5 million, adding more capital for its kidney-disease therapy pipeline.

What happened

The clinical-stage biotech company is developing therapies for kidney disease and added new investment to its Series A round. The financing gives R1 more runway to advance its research and clinical development work.

Kidney disease remains a large chronic-care market with significant unmet medical need, especially for patients whose conditions progress despite existing treatment options.

Why it matters

Biotech funding remains selective, but specialist platforms can still attract capital when they target serious diseases with meaningful commercial and clinical potential.

For R1, the expanded round suggests investor interest in kidney disease as an area where new mechanisms and better disease-modifying therapies could create value.

The bigger picture

Life-sciences investors are still backing focused clinical programmes, but the bar is high. The strongest rounds increasingly go to companies with clear disease targets, credible science and a path toward meaningful clinical inflection points.